EGLT Egalet Corporation

2.63
-0.21  -7%
Previous Close 2.84
Open 2.84
Price To book 0.00
Market Cap 65.84M
Shares 25,034,000
Volume 435,003
Short Ratio 24.68
Av. Daily Volume 300,987

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

sNDA filed December 1, 2016.
OXAYDO
Acute and chronic moderate to severe pain
Phase 3 to be completed 4Q 2017. NDA planned for 2018.
Egalet-002
Moderate to severe chronic pain
Approved January 9, 2017.
Egalet-001 (ARYMO ER)
Abuse-Deterrent Morphine

Latest News

  1. ETFs with exposure to Egalet Corp. : May 26, 2017
  2. Egalet Announces Results of ARYMO® ER Harm Reduction Modeling Analysis
  3. Egalet Announces ARYMO™ ER Data Published in Journal of Opioid Management and American Journal of Drug and Alcohol Abuse
  4. Egalet Announces Scientific Presentations at American Pain Society Meeting
  5. Egalet Corp. :EGLT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
  6. Panel of Leading Pain Management Specialists Highlight Potential Role of Abuse-Deterrent Formulations of Opioids and Non-Narcotics to Help Curb Misuse and Abuse at Egalet Investor Day
  7. Egalet reports 1Q loss
  8. Egalet Reports First Quarter 2017 Financial Results
  9. Egalet to Report First Quarter 2017 Financial Results During Investor Day on May 10, 2017 in New York
  10. Egalet Announces U.S. Food and Drug Administration Acceptance of File for Prior Approval Supplement for OXAYDO® (oxycodone HCl, USP) tablets C-II 10 mg and 15 mg Dosage Strengths
  11. Egalet Corporation Announces Changes to Board of Directors
  12. Egalet to Participate in Spring Investor Conferences
  13. Egalet Deploys Salesforce to Begin Educating Healthcare Providers about ARYMO™ ER
  14. The FDA News That Put The Wind Beneath Egalet Stock's Wings
  15. Egalet Can Tout Abuse-Deterrent Opioid Painkiller
  16. Egalet Corporation (Nasdaq: EGLT) to Ring The Nasdaq Stock Market Closing Bell
  17. Egalet Announces U.S. Food and Drug Administration Does Not Object to Egalet's Distribution of Materials and Communications to Healthcare Professionals Regarding Abuse-Deterrent Properties of ARYMO™ ER via Intranasal Route
  18. DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders it Has Filed a Complaint to Recover Losses Suffered by Investors in Egalet Corporation, Sets Lead Plaintiff Deadline of March 28, 2017 - EGLT
  19. DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Egalet Corporation (EGLT) & Lead Plaintiff Deadline - March 28, 2017
  20. IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Egalet Corporation and Encourages Investors with Losses to Contact the Firm